Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium
de Wit, R.
Gietema, J. A.
De Giorgi, U.
Cafferty, F. H.
Hansen, A. R.
Huddart, R. A.
Sweeney, C. J.
Heng, D. Y. C.
Feldman, D. R.
Vaughn, D. J.
Sternberg, C. N.
AffiliationOncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
MetadataShow full item record
AbstractPurpose: The classification of the International Germ Cell Cancer Collaborative Group (IGCCCG) plays a pivotal role in the management of metastatic germ cell tumors but relies on data of patients treated between 1975 and 1990. Materials and methods: Data on 9,728 men with metastatic nonseminomatous germ cell tumors treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Europe, North America, and Australia. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS). The survival estimates were updated for the current era. Additionally, a novel prognostic model for PFS was developed in 3,543 patients with complete information on potentially relevant variables. The results were validated in an independent data set. Results: Compared with the original IGCCCG publication, 5-year PFS remained similar in patients with good prognosis with 89% (87%-91%) versus 90% (95% CI, 89 to 91), but the 5-year OS increased from 92% (90%-94%) to 96% (95%-96%). In patients with intermediate prognosis, PFS remained similar with 75% (71%-79%) versus 78% (76%-80%) and the OS increased from 80% (76%-84%) to 89% (88%-91%). In patients with poor prognosis, the PFS increased from 41% (95% CI, 35 to 47) to 54% (95% CI, 52 to 56) and the OS from 48% (95% CI, 42 to 54) to 67% (95% CI, 65 to 69). A more granular prognostic model was developed and independently validated. This model identified a new cutoff of lactate dehydrogenase at a 2.5 upper limit of normal and increasing age and presence of lung metastases as additional adverse prognostic factors. An online calculator is provided (https://www.eortc.org/IGCCCG-Update). Conclusion: The IGCCCG Update model improves individual prognostication in metastatic nonseminomatous germ cell tumors. Increasing age and lung metastases add granularity to the original IGCCCG classification as adverse prognostic factors.
CitationGillessen S, Sauve N, Collette L, Daugaard G, de Wit R, Albany C, et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021:JCO2003296.
JournalJournal of Clinical Oncology
- Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
- Authors: Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg CN, Vaughn DJ, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S, International Germ Cell Cancer Classification Update Consortium.
- Issue date: 2021 May 10
- Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
- Authors: Kier MG, Lauritsen J, Mortensen MS, Bandak M, Andersen KK, Hansen MK, Agerbaek M, Holm NV, Dalton SO, Johansen C, Daugaard G
- Issue date: 2017 Feb
- A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
- Authors: Necchi A, Pond GR, Nicolai N, Giannatempo P, Raggi D, Adra N, Hanna NH, Salvioni R, Einhorn LH, Albany C
- Issue date: 2017 Apr
- Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
- Authors: Rolevich AI, Borodin DM, Rabcheuski AN, Ivanitskaya TA, Semenov SA, Artsiushkevich LV, Sukalinskaya AV, Zhavrid EA, Krasny SA, Konoplya NE, Polyakov SL
- Issue date: 2021 Jan
- Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
- Authors: Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT
- Issue date: 2001 Apr 1